MOLECULAR PARTNERS AG

# Signal Note: BVF Partners Initiates Position in Molecular Partners (MOLN) BVF's $5.8M entry into MOLN suggests conviction in the company's clinical pipeline, likely centered on abicipar (anti-VEGF DARPin for wet AMD), which faced prior regulatory setbacks but could represent value if reformulated or repositioned. The timing aligns with potential near-term catalysts around clinical data readouts or partnership developments that Lampert's value thesis may be pricing at a discount to intrinsic worth. Given BVF's concentrated biotech focus, this signals a belief MOLN's valuation has disconnected from downside probability-adjusted pipeline value.